IPAB Repeal Gets a Big Boost—From a Footnote
This article was originally published in RPM Report
CBO’s latest assumptions about Medicare spending over time have an important implication: the trigger for action by the newly created Independent Payment Advisory Board is no longer predicted to occur. That makes industry’s call to repeal the board suddenly more possible--though the Administration won't let IPAB go without a fight.
You may also be interested in...
Pharma’s Adherence Allies: Part D Hearing Underscores Industry Progress in Reframing Rebate Debate
Sen. Bill Nelson is the primary sponsor of legislation to impose rebates on Medicare Part D. But when he held a hearing on the program in his Aging Committee, something surprising happened: everyone wanted to talk about adherence instead.
Beyond ObamaCare: Big Pharma, Health Reform and the 2012 Elections
Most everyone can agree that health care costs are spiraling out of control. President Obama and his Republican challenger Mitt Romney each say they have a plan to cut spending. But while those are being debated, a high-profile group of former Obama advisers are suggesting something much more radical: a systematic change in the way we pay for health care. Could it be a blueprint for a second Obama term?
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?